Eyes on New Product Development

Abstract

Get full access to this article

View all access options for this article.

References

Loftus

Lilly cancer drug should get more study, FDA Advisers Say. Wall Street J. A7, Feb 11, 2022.

Singh

, and Pazdur

Importing oncology trials from China: a bridge over troubled waters?. Lancet. Oncol. 23:323–325, 2022.

Butcher

Mixed response to the CMS decision on coverage for aducanumab. Neurol. Today. 22:1–2, 2022.

Chiong

, Tolchin

B.D.

, Bonnie

R.J.

, et al. Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent. AAN Posit. Statement. 98:154–159, 2022.

Novack

G.D.

Unapproved drugs—A fix to an unintended consequence of an FDA policy. Ocul. Surf. 21:351–354, 2021.

Gunter

S.J.

, Kesselheim

A.S.

, and Rome

B.N.

Medicaid spending on drugs marketed without US Food and Drug Administration Approval in 2020. JAMA Intern. Med. 2022 [Epub ahead of print]; DOI: 10.1001/jamainternmed.2021.7614.

Novack

G.D.

Pipeline: What does the Food and Drug Administration safety and innovation act mean for you?. Ocul Surf, 11:206–209, 2013.